الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 130 |  |  |
| | | from | 130 | | |
Abstract
B-CLL is the most common type of leukemia in western countries. The incidence is estimated to more than 6 per 100,000 people annually. The median age at diagnosis is growing globally, so that now exceeds 70 years. It should be noted that the age at treatment initiation is several years older than the age at diagnosis, depending on the duration of observation without treatment.(Jakšić et al., 2018). CLL displays a high heterogeneity in its clinical course, which makes the onset time and the choice of therapy difficult to determine.(Robak, 2014) Aim: This study aimed to 1-evaluate the expression of LAIR1 in patients with CLL. 2-investigate the prognostic relevance of LAIR1 expression on B-cell CLL. The study revealed the following results: • TLC, lymphocytic count were significantly elevated in patient group compared to control, while there was a significant decrease in hemoglobin and platelet count in patient group compared to control group. • There was a significant correlation between CD305 with Hb and PLT. And also there was a negative correlation between CD305 with age and WBCS. TLC was negatively correlated with Hb and PLT count. • There was a significant decrease in hemoglobin and platelet count in CD305 negative group compared to CD305 positive group. • TLC was significantly increased in CD305 negative group compared to CD305 positive group. • There was a significant increase of CD38 expression in CD305 negative group compared to CD305 positive group. • There was an increase in number of cases receiving Treatment among CD305 negative group compared to CD305 positive group. • Level of CD 305 among cases received or not received Treatment. CD305 was significantly increased in cases not received Treatment compared to cases receive Treatment. • At the end of follow up period (12 months), as regard CD305, 19.0% cases not receive Treatment at 6 months interval in CD 305 negative group, also 65.5% cases not receive Treatment at 6 months interval in CD305 positive cases.